Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Date:3/13/2009

ximab against EGFR-overexpressing tumors.

    European Society for Medical Oncology (ESMO) Presentation, March 23-25,
    2009

Additionally, YM announced that a further poster entitled "Differences in clinical safety profiles of nimotuzumab and cetuximab, EGFR-targeting antibodies, as a consequence of divergent monovalent/bivalent binding profiles of these agents" has been accepted for presentation at the European Society for Medical Oncology's 7th International Symposium on Targeted Anticancer Therapies 2009 in Amsterdam, Netherlands being held March 23rd - 25th, 2009 (Abstract code C02).

"The three posters referenced are a partial reflection of the current, extensive activity at YM, its licensees and at other nimotuzumab developers worldwide aimed at explaining the benign toxicity profile of nimotuzumab given its established anti-tumour activity," said David Allan. "We believe that these compelling results, combined with the evidence of efficacy of nimotuzumab in the correct settings, and with the appropriate regimens, should convince investors that the market is inappropriately discounting the value of the nimotuzumab clinical program."

YM is conducting two international, multi-center, randomized, double-blinded Phase II trials with nimotuzumab in combination with radiation. These two indications - brain metastasis from lung cancer and palliative therapy in non-small cell lung cancer (NSCLC) - represent indications of high unmet need. In the US, approximately 140,000 cases of brain metastasis are diagnosed annually and the frequency is increasing as more patients live longer. The incidence of lung cancer in the US is approximately 215,000 cases of which 80-85% is NSCLC. Recruitment of these trials is expected to be complete in 2010.

Notice for AIM Compliance

The Company was notified on 27 February 2009 that on 17 February 2009, Mr. Gabe Hoffman directly and through Accipi
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
2. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
5. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
6. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
7. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
8. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 The role of the Medical ... one thing hasn,t changed: face-to-face meetings are seen as ... Key Opinion Leaders. Yet at the same ... type of interaction, field medical teams within the pharmaceutical ... This is just one of the challenges addressed in ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... in the Proceedings of the National Academy ... when ibrutinib (IMBRUVICA ® ) was combined with ... tumor growth was enhanced suggesting a greater response ... and solid tumors with the combination. IMBRUVICA is ...
(Date:2/27/2015)... , Israele, February 27, 2015 ... suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto congestizio ... trial sull,uomo-     ... sviluppo di nuovo sistema per il monitoraggio cardiaco ... ha annunciato oggi di aver concluso una raccolta ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... Feb. 21, 2012  Quest Diagnostics Incorporated (NYSE: ... diagnostic testing, information and services, launched today at ... (EHR) implementation guarantee for hospitals looking to quickly ... through its award winning Care360® EHR ...
... Texas, Feb. 21, 2012  Positron Corporation (OTCBB: POSC), through ... is proud to announce that on February 16, 2012, ... ARRONAX Cyclotron Facility in Nantes, France.  ... to be received by a private, non-government, entity in ...
Cached Medicine Technology:Quest Diagnostics Offers Industry-First 30-Day Ambulatory EHR Implementation Guarantee for Hospitals and IDNs 2Quest Diagnostics Offers Industry-First 30-Day Ambulatory EHR Implementation Guarantee for Hospitals and IDNs 3Quest Diagnostics Offers Industry-First 30-Day Ambulatory EHR Implementation Guarantee for Hospitals and IDNs 4MIT Receives First ARRONAX Shipment, Launching Strontium-82 Validation Project 2
(Date:2/28/2015)... 28, 2015 The Heart Fit Clinic ... distributor of the machine. The Heart Fit Clinic is ... like a franchise model. The goal is to scale ... heart disease. To buy External Counterpulsation machines ... help individuals through this process and achieve the desired ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... at the 2015 Japan Architecture & Construction Materials Show, ... They’ll join more than 1,000 suppliers and top manufacturers ... , Reclaimed wood products sourced and manufactured ... facilities have found popularity in Japan at restaurants, hotels, ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 ... organization has sponsored visitor health insurance programs for visitors ... years. Most Indian elderly parents traveling to the United ... such as diabetes and blood pressure. These diseases are ... not even list them as medical conditions. There were ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... Founder of ... who accelerated her recovery. Lack of friends connected to poorer health Company aims to reduce ... ... The Friendship Stone will mark Friendship Week starting August 2nd. Founder, Cathy Raff, will dedicate ...
... , , New Report Is ... Lower Costs , , KANSAS CITY, Mo., ... marks for communicating effectively and treating them respectfully, according to a new patient experience ... 700 doctors are available at http://kcq i c.org ...
... , , OLYMPIA, ... prescription medications since the launch of the free statewide prescription assistance program. ... was launched in August, 2008. The program has no restrictions to membership, ... fill out. Anyone interested in receiving a free card can visit ...
... , , WARSAW, Ind., July ... independent provider of products to the global orthopaedic device industry and other ... results for the period ending July 4, 2009 before the market opens ... call at 8:00 a.m. ET on Thursday, August 6, 2009. , ...
... , , HOUSTON, July 21 US Oncology, ... on Thursday, August 6, 2009. , , A ... ET following distribution of the earnings release. Additional information will be available on ... on the day of the earnings announcement. , , ...
... IHA Completes the Second Chapter of the ... for Measurement Years 2006 - 2009 , ... (IHA) is pleased to announce the publication of "The Second Chapter," a ... for performance (P4P) program - the largest non-governmental physician incentive program in ...
Cached Medicine News:Health News:The Friendship Stone Helps Friends Remain Healthy 2Health News:The Friendship Stone Helps Friends Remain Healthy 3Health News:The Friendship Stone Helps Friends Remain Healthy 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 2Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 3Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 4Health News:Kansas City Patients Rate Their Doctors in Most Reliable Survey of Its Kind 5Health News:Free Drug Card Has Saved Washington Residents $2.6 Million 2Health News:Symmetry Medical to Report Second Quarter 2009 Financial Results on August 6, 2009 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:Integrated Healthcare Association Releases White Paper on Pay for Performance 2
Used with Single Tantalum Clip (E5381 854) and Double Tantalum Clip (E5381 853). Overall length: 7.2 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
2 mm x 0.75 mm. Overall length: 125 mm, 4.9 inches....
...
Medicine Products: